Catalent (CTLT) versus Its Competitors Critical Survey
Catalent (NYSE: CTLT) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Catalent to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.
Risk and Volatility
Catalent has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Catalent’s rivals have a beta of 34.20, indicating that their average stock price is 3,320% more volatile than the S&P 500.
This table compares Catalent and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Catalent||$2.08 billion||$109.80 million||45.68|
|Catalent Competitors||$8.17 billion||$1.09 billion||127.03|
Catalent’s rivals have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Catalent and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
99.5% of Catalent shares are owned by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Catalent shares are owned by company insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Catalent and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalent presently has a consensus price target of $43.71, indicating a potential upside of 10.00%. As a group, “Pharmaceuticals” companies have a potential upside of 20.90%. Given Catalent’s rivals higher probable upside, analysts clearly believe Catalent has less favorable growth aspects than its rivals.
Catalent rivals beat Catalent on 7 of the 13 factors compared.
Catalent Company Profile
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.